The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients

Abstract

Introduction Although the clinical effects of infliximab therapy in rheumatoid arthritis have been documented extensively, the biological effects of this intervention continue to be defined. We sought to examine the impact of infliximab therapy on the serum proteome of rheumatoid arthritis patients by means of a mass spectrometry-based approach.

Quantitative Proteomics Using iTRAQ Labeling and Mass Spectrometry

“…Pendyala et al (2010) used iTRAQ TM to show that the vitamin E binding protein, afamin, is downregulated after viral infection in a study of HIV-1-associated neurocognitive disorder (HAND). Although serum samples present a problem for iTRAQ TM because of high concentrations of a few major proteins, the work of Dwivedi et al (2009) illustrates how this was overcome in a study of the proteomic effects of anti-TNF-alpha treatment of rheumatoid arthritis patients. These examples illustrate the wide variety of applications of iTRAQ TM to the most common of all human health problems.…”

Application of Novel Quantitative Proteomic Technologies to Identify New Serological Biomarkers in Autoimmune Diseases

“…Recent proteomics technologies have enabled us to screen these markers from proteins extracted from tissues and sera from patients (Hueber and Robinson, 2006). Accordingly, there are many proteomic studies that analyzed protein profiles and searched new biomarkers in autoimmune diseases (Dwivedi et al, 2009;Ferraccioli et al, 2010;Ling et al, 2010;Serada et al, 2010;Takeuchi et al, 2007). The quantitative proteome analysis by mass spectrometry (MS) usually involves differential isotope labeling of proteins and peptides metabolically, enzymatically or chemically using…”

“…The capability of iTRAQ for protein quantitation has been verified by analyzing standard mixtures of proteins of known proportions (Aggarwal et al, 2006). The iTRAQ approach has now been successfully used to identify and quantify the proteins in variety of prokaryotic and eukaryotic samples (Aggarwal et al, 2006;Cong et al, 2006;DeSouza et al, 2005;Dwivedi et al, 2009;Hardt et al, 2005;Zhang et al, 2005).…”

“…Before we publish our results, a study was published and reported the serum proteome of RA patients treated with anti-TNF mAb therapy. They provided evidence that iTRAQ strategy can be used to obtain quantitative data that reflect changes in the serum proteome after targeted therapeutic interventions (Dwivedi et al, 2009). We used iTRAQ technology to obtain profiles of serum proteome in RA patients before and after TNF inhibitor treatment.…”

Role of laboratory biomarkers in monitoring and prediction of the effectiveness of treatment of rheumatic diseases using genetically engineered drugs

“…Dwivedi и соавт. [17] через 12 нед после начала терапии ИНФ, которые обнаружили у пациентов с хо-рошим ответом на препарат 20% изменение концентрации 39 белков, регулируемых ФНОα или NF-kB. По данным S. Fabre и соавт.…”